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ABSTRACT (236 words) 
Introduction: Contemporary generalizable data on the demographics and management 
of outpatients with stable coronary artery disease (CAD) in routine clinical practice are 
sparse. Using data from the CLARIFY registry we describe gender- and age-related 
differences in baseline characteristics and management of these patients across broad 
geographic regions.  
Methods: This international, prospective, observational, longitudinal registry, enrolled 
stable CAD outpatients from 45 countries in Africa, Asia, Australia, Europe, the Middle 
East, and North, Central and South America.  
Results: Baseline data were available for 33,280 patients. Mean (SD) age was 64 (10.5) 
years and 22.5% of patients were female. The prevalence of CAD risk factors was 
generally higher in women than men. Women were older (66.6 vs 63.4 years), more 
frequently diagnosed with diabetes (33% vs 28%), hypertension (79% vs 69%), and 
higher resting heart rate (69 vs 67 bpm), and were less physically active. Smoking and a 
history of myocardial infarction were more common in men. Women were more likely to 
have angina (28% vs 20%), but less likely to have undergone revascularization 
procedures. CAD was more likely to be asymptomatic in older patients perhaps because 
of reduced levels of physical activity. Prescription of evidence-based medication for 
secondary prevention varied with age, with patients ≥75 years less often treated with 
beta blockers, aspirin and angiotensin-converting enzyme inhibitors than patients <65 
years. 
Conclusions: Important gender-related differences in clinical characteristics and 
management continue to exist in all age groups of outpatients with stable CAD. 
Keywords: 
Angina; Coronary artery disease; Gender; Age  
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1. Introduction  
Average life expectancy has increased by 10 years in the last 30 years with 
improvements in the field of cardiology contributing for at least 7 years [1]. Despite such 
success, coronary artery disease (CAD) remains the leading cause of mortality and 
morbidity in the world [24]. It follows that the cardiovascular community has not solved 
the problem, but has delayed the occurrence of CAD-related mortality and changed the 
demographics of patients with CAD, with a shift of disease burden toward older patients, 
in both men and women [5,6]. 
Aging has been associated with a reduced likelihood of receiving effective cardiac 
therapies [710]. Furthermore, the prevention and treatment of CAD may not be as 
effective in women as in men [1118], suggesting that for optimal treatment of CAD it is 
necessary to recognize the impact of age and gender differences on the outcomes of 
care.  
Surprisingly, there is a paucity of contemporary data regarding the clinical characteristics 
and management of outpatients with stable CAD. The majority of data are restricted to a 
particular manifestation of disease such as angina or acute coronary syndrome [6, 14, 
1924] and are limited to a specific country or a geographic area. Furthermore, gender 
and age are usually analyzed separately [21, 22, 2426]. Our goal is to describe the 
gender- and age-based differences in baseline characteristics and management of 
outpatients with stable CAD using a large contemporary database from 45 countries.  
2. Methods 
2.1 Study design 
CLARIFY is an ongoing international, prospective, observational, longitudinal cohort 
study in stable CAD outpatients with a 5-year follow-up [27]. Patients were enrolled in 45 
countries in Africa, Asia, Australia, Europe, the Middle East, and North, Central and 
South America. They were treated according to usual clinical practice at each institution, 
with no specific tests or therapies defined in the study protocol. CLARIFY is registered in 
the ISRCTN registry of clinical trials with the number ISRCTN43070564 and approved 
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by local ethical committees. All subjects provided written informed consent in 
accordance with national and local guidelines. 
2.2 Study population 
Outpatients with stable CAD had to meet at least one of the following criteria to be 
eligible for enrollment [27]: documented myocardial infarction > 3 months previously; 
at least one angiographically proved >50% diameter coronary artery stenosis; chest pain 
with myocardial ischemia proven by stress echocardiography (ECG), or myocardial 
imaging; and history of coronary artery bypass graft (CABG) or percutaneous coronary 
intervention (PCI) carried out > 3 months previously. Patients were not eligible if they 
had been hospitalized for cardiovascular disease (CVD) within the last 3 months 
(including revascularization), or had planned revascularization, or had conditions 
hampering participation or 5-year follow-up such as limited cooperation or legal capacity, 
advanced heart failure, severe valve disease, history of valve repair/replacement, or 
serious non-cardiovascular disease limiting life expectancy (cancer, drug abuse, etc.), 
Patients were recruited between November 2009 and July 2010. To ensure a balanced 
representation of participating countries, a general target enrollment for any participating 
country was 25 patients per million inhabitants (range 12.5–50). A broad range of 
physicians were involved in the selection of patients including cardiologists, general 
practitioners and internists. Each physician recruited a maximum of 15 outpatients with 
stable CAD as defined by the protocol. Patients were enrolled in each practice over a 
brief period of time to provide near, if not consecutive, patient enrollment.  
2.3 Baseline data collection and data management 
Data regarding patient demographics, medical history, risk factors, employment status, 
physical examination, heart rate (determined by both pulse palpation and 12-lead 
electrocardiography) using the most recent ECG within 6 months in clinically stable 
patients, laboratory values (if available), and current chronic medical treatments were 
collected by the participating physician using an electronic case report form and sent to 
the data management center. Here, data were checked for completeness and internal 
consistency. Data quality control was performed onsite in 5% of sites chosen at random 
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in each country. At each of these sites, 100% of case report forms for patients enrolled 
at that site were monitored for source documentation and accuracy.  
2.4 Statistical analysis 
Data were collected and analyzed by an independent statistics center, the Robertson 
Center for Biostatistics, University of Glasgow, UK. Continuous variables are presented 
as means and standard deviations (SDs) in case of normal distribution, or medians and 
interquartile ranges (IQRs) and ranges in case of non-normal distribution. Categorical 
data are presented as counts and percentages.   
 
3. Results 
The CLARIFY registry screened a total of 33 432 patients from 45 countries. Baseline 
data were available for 33 280; 47 patients did not meet the inclusion criteria and 105 did 
not provide consent. 
The mean (SD) age of the population surveyed was 64 (10.5) years. Women 
represented 22.5% of the population overall and were slightly older than the men with a 
mean age of 66.6 (10.0) years compared with 63.4 (10.5) years in men. A total of 17 206 
patients were <65 years old, 10 812 were aged 65-74 years, and 5196 were aged ≥75 
years. 
3.1 Gender differences in the presentation and clinical management of outpatients with 
CAD 
The baseline data for men and women are presented in Tables 1 and 2. A number of 
important differences in clinical characteristics and management were identified. 
Compared with men, women were on average 3.1 years older and had higher resting 
heart rates (69.0 bpm versus 67.9 bpm, pulse palpation) and systolic blood pressure 
(133.3 mmHg versus 130.3 mmHg). Women were less physically active with 23.4% 
performing no physical activity compared with 14.3% of men. Only 9.6% of women 
performed at least 20 minutes of vigorous physical activity at least three times per week 
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compared with 17.3% of men, and only 11.9% of women versus 18.2% of men 
performed such activity once or twice per week.  
In terms of cardiovascular history, women had a shorter duration of CAD (4 years versus 
5 years, P<0.0001) and were more frequently diagnosed with diabetes, hypertension, 
stroke, and transient ischemic attack. Smoking, a history of myocardial infarction, and 
peripheral arterial disease (PAD) were more common in men. Women presented with 
angina more often than men (28% versus 20%) and this was true for all angina classes 
defined by the Canadian Cardiovascular Society grading scale (Fig. 1). In contrast, 
women were less likely to have undergone PCI (54.9% versus 59.8%) or CABG (17.8% 
versus 25.0%) (Fig. 2). 
Women were less likely to have undergone cardiac investigations. Coronary 
angiography was performed in 79.9% of women versus 87.0% of men. Noninvasive tests 
for myocardial ischemia were done in 58.3% of women compared with 62.9% in men. In 
those patients with data from noninvasive testing, evidence for myocardial ischemia was 
observed more often in women than men (17.3% vs 15.9%).  
Women were prescribed angiotensin-converting enzyme (ACE) inhibitors and lipid-
lowering drugs significantly less frequently than men, but received antianginal agents, 
antidiabetes drugs, non-steroidal anti-inflammatory, proton pump inhibitor, and thyroid 
hormone replacement more often than men (Fig. 2). There was no significant difference 
in the use of beta-blockers between the sexes. 
3.2 Age-related differences in the presentation and clinical management of outpatients 
with CAD 
Table 1 demonstrates that concomitant conditions were widely prevalent among the 
study population. The proportion of those with atrial fibrillation, transient ischemic attack, 
hospitalization for congestive heart failure, asthma/chronic obstructive pulmonary 
disease (COPD), PAD, dyslipidemia, hypertension, and diabetes increased 
progressively with age. Tobacco and alcohol use decreased relative to age.  
There were significant age-related differences among both men and women (Table 1). 
Compared with those aged <65 years, patients aged ≥75 years had higher systolic blood 
pressure (133.55 [16.97] mmHg versus 129.38 [16.47] [values were the same in both 
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men and women]), lower body mass index (BMI) values (26.1 kg/m2 versus 27.9 kg/m2 
in women and 26.5 kg/m2 versus 27.6 kg/m2 in men) and were less likely to be current 
smokers (2.3% versus 11.5% in women and 4.5% versus 19.6% in men). Patients ≥75 
years had lower resting heart rates measured by pulse palpation (67.5 bpm versus 69.1 
bpm) or by ECG (66.6 bpm versus 67.8 bpm) (values were the same in both men and 
women). 
In both men and women, older patients were more often asymptomatic, with angina 
present in 20.7% of women and 17.1% of men aged ≥75 years compared with 32.7% of 
women and 22.9% of men aged <65 years (P<0.0001). This may be due to reduced 
physical activity below the ischemic threshold, sedentary lifestyle or locomotor disability. 
Nearly one third of women (31.3%) and 21.9% of men aged ≥75 years performed no 
physical activity compared with 19.8% of women and 12.2% of men aged <65 years 
(P<0.0001). 
Older patients had significantly higher rates of hypertension (74.7% versus 64.7% in 
men and 82.8% versus 73.2% in women), PAD (14.7% versus 7.6% in men and 9.9% 
versus 6.8% in women), hospitalization for chronic heart failure (7.1% versus 3.6% in 
men and 8.3% versus 4.4% in women), asthma or COPD (11.0% versus 5.0% in men 
and 9.1% versus 7.6% in women), and stroke (6.4% versus 2.7% in men and 5.8% 
versus 4.1% in women). Older men had a higher rate of diabetes (28.8% versus 26.7%); 
in women, there was no significant difference in rates of diabetes with age.  
Men of all ages were significantly more likely to have undergone CABG than women 
(Table 1). In patients <65 years of age percutaneous coronary interventions were more 
common in men than women, but in older patients the proportion of men and women 
having these interventions was similar.  
Table 2 shows the principal evidence-based medications prescribed across age strata. 
Compared with younger patients, those over 75 years were less often treated with beta-
blockers (68.4% versus 78.4% in men and 69.1% versus 77.9% in women), aspirin 
(79.2% versus 91.5% in men and 82.8% versus 89.1% in women), and ACE inhibitors 
(47.0% versus 55.5% in men and 39.6% versus 49.7% in women), but received more 
often calcium channel blockers (31.7% versus 22.0% in men and 34.1% versus 29.6% in 
women), angiotensin II receptor blockers (29.0% versus 22.1% in men and 38.5% 
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versus 27.3% in women), long-acting nitrates (26.8% versus 19.1% in men and 30.1% 
versus 23.5% in women) and diuretics (37.6% versus 21.7% in men and 44.5% versus 
32.3% in women).  
 
4. Discussion 
Our analysis reveals a number of gender- and age-related differences among stable 
outpatients with CAD. These findings have important clinical implications. The positive 
impact of improvements in the prevention and treatment of CAD has resulted in an 
increased number of elderly patients of both genders living as outpatients and needing 
targeted care. In terms of risk factors, older patients have lower heart rates compared 
with those aged <65 years, but higher systolic blood pressure, a higher prevalence of 
diabetes, and are less likely to be current smokers. There were also significant 
differences in current medications used by different age groups. Increasing age was 
associated with a reduced likelihood of receiving effective cardiac therapies such as 
ACE inhibitors, lipid-lowering agents and beta-blockers, but more symptomatic therapy.  
This paradox of less intensive use of evidence based preventive therapies in patients 
recognized to be at higher risk may reflect attempts by physicians to limit the number of 
cardiovascular medications in elderly patients who often need other drugs for comorbid 
conditions, or to the questionable belief that in elderly patients symptom relief is more 
important than prognosis.    
A number of gender-related differences were also relevant. When compared with their 
age-matched male counterparts, women with CAD were older, less likely to be current 
smokers, but performed less or no physical activity.  Women had more history of 
diabetes, high blood pressure and angina, yet were less likely than men to undergo 
coronary artery angiography as well as non-invasive tests for myocardial ischemia. This 
latter discrepancy is probably related to the rather low specificity of exercise testing in 
women. As a consequence, women are less likely than men to undergo PCI or CABG.  
Pharmacological therapy for CAD also differed between the sexes. Women were more 
likely to receive calcium channel blockers, but less ACE inhibitors, more anti-diabetic 
drugs, but less statins than men. There were no differences in the use of beta-blockers 
between men and women.   
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Other studies have also shown that men are significantly more likely than women to 
undergo revascularisation with both CABG and PCI [14, 17, 28]. The reason for this 
discrepancy is unclear. Physicians appear to be less concerned about CAD in women 
as, despite the higher degree of angina, women received fewer referrals for coronary 
angiography. It is also possible that the perception of CAD is less in women than in men 
so that they consult their physicians less frequently. In the past, revascularisation 
procedures were associated with more complications in women than men, but technical 
advances in the last decade have greatly improved outcomes in women [29]. Other 
reasons for the discrepancy could be linked to differences in clinical judgment or to 
gender differences in the severity and extent of diseased coronary arteries. In the 
current study, men had more severe coronary stenoses than women, which may in part 
explain the lower rate of procedures in women.  However, women were also less likely to 
be receiving recommended treatment with ACE inhibitors and lipid-lowering drugs than 
their male counterparts. The physician's perception of either anticipated adverse drug 
reactions or less severe disease may influence their decision to prescribe these 
medications for women [30]. When taken together, these data suggest the need to 
increase awareness of CAD in women both among physicians and the female 
population.   
Other studies have reported similar findings [7, 9, 11-12, 14, 17, 25].  However, many of 
these were completed over a decade ago and may not reflect current clinical practice. 
Furthermore, many have focused on specific subgroups of patients with a particular 
manifestation of disease such as stable angina or acute coronary syndromes. Others 
focused on populations from randomized clinical trials with their more narrowly defined 
inclusion/exclusion criteria. The CLARIFY data are an important addition to the literature 
as they provide robust contemporary information about the characteristics, management, 
and outcomes of a large population of stable CAD outpatients across a variety of 
geographic and practice settings. Furthermore, the entire clinical management pathway 
of patients with stable CAD was examined, rather than restricting the study to a limited 
number of healthcare interventions.  
‘Real-life’ studies such as CLARIFY offer the advantage that they provide data on a 
heterogeneous patient population that includes groups who are often under-represented 
in randomized clinical trials. However, as a non-randomized, observational study, 
CLARIFY is subject to certain limitations and potential biases. We did not collect 
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information about the adverse effects related to the use of medications, or reasons by 
patients as well as physicians for not using the medications or undergoing cardiac 
interventions. Finally, we did not examine the effect of potential confounders when 
evaluating gender- and age-differences in patients’ characteristics and CAD 
management. However, despite these limitations, the study provides a useful insight into 
current practice with regard to the characteristics and management of outpatients with 
stable CAD. 
The CLARIFY data reveal that despite the attention that has been focused on gender 
and age-related differences over the past 20 years, the disparities have remained largely 
unchanged over time. Women and the elderly form a major part of the population that 
characterizes contemporary outpatients with stable CAD , yet, despite appearing at 
higher risk of subsequent events, based on increased prevalence of risk factors and 
more frequent history of CV events, they receive less intensive preventive evidence 
based therapies. In high risk patients, particularly those with established CAD, vigorous 
preventive measures are warranted at all ages and in both sexes. Further work is 
required to improve our understanding of the age and gender differences in patient 
characteristics and CAD management identified in the CLARIFY registry. 
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Table 1 Clinical characteristics and patient management of men and women in the 
CLARIFY registry.  
Fig. 1. Distribution of Canadian Cardiovascular Society angina classes in men and 
women. 
Fig. 2. Clinical characteristics and management of CAD patients by gender. 
 
 
 
 
 
